Deal Watch: Galenica Offers For Relypsa, But Other Suitors May Emerge
Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.
You may also be interested in...
Garland Takes Helm Of Portola At A Crucial Time
Portola touts exec's commercial management experience with Genentech success stories Avastin and Tarceva.
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
Public Biopharma Financings Plunge In 2016, But Is It A Sign Of Health?
There were far fewer follow-on and other non-IPO public biopharma company financings during the first half of 2016 compared with the same period in 2015, but the more normal level of investment may mean that the market for therapeutic companies' stocks is healthier than in recent years.